Immunocore Holdings plc Increase (Decrease) in Other Operating Assets
Immunocore Holdings plc (IMCR) reported Increase (Decrease) in Other Operating Assets of $605.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-06
- Immunocore Holdings plc increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $755.00K.
- Immunocore Holdings plc increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$150.00K, a 109.54% decline year-over-year.
- Immunocore Holdings plc increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $4.71M.
- Immunocore Holdings plc increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $5.00M, a 8.49% increase year-over-year.
- Immunocore Holdings plc increase (decrease) in other operating assets for fiscal 2025 was $6.18M, a 46.20% increase from fiscal 2024.
- Immunocore Holdings plc increase (decrease) in other operating assets for fiscal 2024 was $4.22M, a 53.92% decline from fiscal 2023.
- Immunocore Holdings plc increase (decrease) in other operating assets for fiscal 2023 was $9.17M, a 93.89% increase from fiscal 2022.
- Immunocore Holdings plc increase (decrease) in other operating assets for fiscal 2022 was $4.73M.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $755.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $605.00K 10-Q · filed 2026-08-06 | $5.31M derived: sum of 3 quarters · filed 2026-08-06 | $10.31M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$150.00K 10-Q · filed 2026-05-06 | $4.56M derived: sum of 2 quarters · filed 2026-05-06 | $9.55M derived: sum of 3 quarters · filed 2026-05-06 | $4.45M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $9.70M derived: sum of 2 quarters · filed 2026-02-25 | $4.60M derived: sum of 3 quarters · filed 2026-08-06 | $6.18M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$102.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.47M 10-Q · filed 2025-11-06 | $1.18M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.53M 10-Q · filed 2026-08-06 | -$3.82M derived: sum of 3 quarters · filed 2026-08-06 | $790.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $1.57M 10-Q · filed 2026-05-06 | $1.28M derived: sum of 2 quarters · filed 2026-05-06 | $5.89M derived: sum of 3 quarters · filed 2026-05-06 | $4.40M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.32M derived: sum of 2 quarters · filed 2026-02-25 | $2.83M derived: sum of 3 quarters · filed 2026-02-25 | $4.22M 10-K · filed 2026-02-25 | $8.05M 10-K · filed 2025-02-26 |
| 2024-09-30 | $4.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.12M derived: sum of 2 quarters · filed 2025-11-06 | $4.51M 10-Q · filed 2025-11-06 | $11.01M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | -$1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$92.00K 10-Q · filed 2025-08-07 | $6.40M derived: sum of 3 quarters · filed 2026-02-25 | $5.51M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $1.40M 10-Q · filed 2025-05-07 | $7.89M derived: sum of 2 quarters · filed 2026-02-25 | $6.99M derived: sum of 3 quarters · filed 2026-02-25 | $10.53M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $6.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.60M derived: sum of 2 quarters · filed 2026-02-25 | $9.13M derived: sum of 3 quarters · filed 2026-02-25 | $9.17M 10-K · filed 2026-02-25 | $15.01M 10-K · filed 2024-02-28 |
| 2023-09-30 | -$895.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.64M derived: sum of 2 quarters · filed 2024-11-06 | $2.68M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.57M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $38.00K 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | $4.73M 10-K · filed 2025-02-26 | ||||
| 2021-12-31 | -$361.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |